- Home
- SKYE vs RGT Comparison
SKYE vs RGT Comparison
Compare SKYE & RGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- RGT
- Stock Information
- Founded
- SKYE 2012
- RGT 1986
- Country
- SKYE United States
- RGT United States
- Employees
- SKYE N/A
- RGT N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- RGT Trusts Except Educational Religious and Charitable
- Sector
- SKYE Health Care
- RGT Finance
- Exchange
- SKYE Nasdaq
- RGT Nasdaq
- Market Cap
- SKYE 80.7M
- RGT 67.6M
- IPO Year
- SKYE N/A
- RGT N/A
- Fundamental
- Price
- SKYE $2.95
- RGT $11.00
- Analyst Decision
- SKYE Buy
- RGT
- Analyst Count
- SKYE 6
- RGT 0
- Target Price
- SKYE $18.67
- RGT N/A
- AVG Volume (30 Days)
- SKYE 169.1K
- RGT 22.4K
- Earning Date
- SKYE 02-13-2025
- RGT 01-01-0001
- Dividend Yield
- SKYE N/A
- RGT 1.43%
- EPS Growth
- SKYE N/A
- RGT N/A
- EPS
- SKYE N/A
- RGT 0.92
- Revenue
- SKYE N/A
- RGT N/A
- Revenue This Year
- SKYE N/A
- RGT N/A
- Revenue Next Year
- SKYE N/A
- RGT N/A
- P/E Ratio
- SKYE N/A
- RGT $11.42
- Revenue Growth
- SKYE N/A
- RGT N/A
- 52 Week Low
- SKYE $2.31
- RGT $7.84
- 52 Week High
- SKYE $19.41
- RGT $11.08
- Technical
- Relative Strength Index (RSI)
- SKYE 47.80
- RGT 43.08
- Support Level
- SKYE $2.53
- RGT $10.87
- Resistance Level
- SKYE $4.25
- RGT $11.07
- Average True Range (ATR)
- SKYE 0.43
- RGT 0.14
- MACD
- SKYE 0.10
- RGT 0.02
- Stochastic Oscillator
- SKYE 28.84
- RGT 41.27
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.